ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.854,19
-0,12%
S&P 500
5.753,88
0,15%
US Dollar vs BRL
5,4441
0,11%
Bitcoin
65.576,95
0,60%
Brent Oil
71,015
0,09%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vaxcyte Inc (PCVX)

  7. Vaxcyte Inc (PCVX) Notícias

PCVX

Vaxcyte (PCVX)

Vaxcyte Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PCVX
DataHoraFonteTítuloCódigoCompanhia
18/09/202417:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
17/09/202417:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCVXVaxcyte Inc
11/09/202417:05GlobeNewswire Inc.Vaxcyte to Present at the 2024 Cantor Global Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
06/09/202417:05GlobeNewswire Inc.Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:PCVXVaxcyte Inc
06/09/202409:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCVXVaxcyte Inc
05/09/202418:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PCVXVaxcyte Inc
05/09/202400:58GlobeNewswire Inc.Vaxcyte Announces Pricing of $1.3 Billion Public OfferingNASDAQ:PCVXVaxcyte Inc
03/09/202417:01GlobeNewswire Inc.Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:PCVXVaxcyte Inc
03/09/202408:07GlobeNewswire Inc.Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
02/09/202419:40GlobeNewswire Inc.Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
06/08/202417:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCVXVaxcyte Inc
06/08/202417:05GlobeNewswire Inc.Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
24/05/202418:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PCVXVaxcyte Inc
08/05/202417:05GlobeNewswire Inc.Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
02/04/202417:05GlobeNewswire Inc.Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
04/03/202410:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsNASDAQ:PCVXVaxcyte Inc
27/02/202418:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PCVXVaxcyte Inc
27/02/202418:01GlobeNewswire Inc.Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
15/02/202418:05GlobeNewswire Inc.Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:PCVXVaxcyte Inc
02/02/202420:39GlobeNewswire Inc.Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:PCVXVaxcyte Inc
01/02/202418:05GlobeNewswire Inc.Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:PCVXVaxcyte Inc
31/01/202401:37GlobeNewswire Inc.Vaxcyte Announces Pricing of $750 Million Public OfferingNASDAQ:PCVXVaxcyte Inc
29/01/202410:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
16/01/202418:01GlobeNewswire Inc.Vaxcyte Appoints Whitney Jones as Chief People OfficerNASDAQ:PCVXVaxcyte Inc
04/01/202418:01GlobeNewswire Inc.Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) FranchiseNASDAQ:PCVXVaxcyte Inc
04/12/202320:35GlobeNewswire Inc.VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateNASDAQ:PCVXVaxcyte Inc
29/11/202318:46Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
28/11/202310:30GlobeNewswire Inc.Vaxcyte Appoints Jacks Lee to Board of DirectorsNASDAQ:PCVXVaxcyte Inc
27/11/202318:00GlobeNewswire Inc.Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNASDAQ:PCVXVaxcyte Inc
09/11/202310:30GlobeNewswire Inc.Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PCVX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
PDGR3
PDG REALT ON
BOV
AZEV4
AZEVEDO PN
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
CBEE3
AMPLA ENERG ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AZEV3
AZEVEDO ON
BOV
RNEW4
RENOVA PN
BOV
HAGA3
HAGA ON
BOV
TCSA3
TECNISA ON
BOV
GFSA3
GAFISA ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados